Match!
Matthew R. Farren
Ohio State University
CancerImmunologyCachexiaMedicineImmune system
16Publications
5H-index
101Citations
What is this?
Publications 14
Newest
#1Erin E. Talbert (OSU: Ohio State University)H-Index: 17
#2Heather L. Lewis (OSU: Ohio State University)H-Index: 3
Last. Denis C. Guttridge (OSU: Ohio State University)H-Index: 42
view all 16 authors...
7 CitationsSource
#1Erin E. Talbert (OSU: Ohio State University)H-Index: 17
#2Jennifer Yang (OSU: Ohio State University)H-Index: 5
Last. Gregory B. Lesinski (OSU: Ohio State University)H-Index: 29
view all 15 authors...
Involuntary weight loss, a part of the cachexia syndrome, is a debilitating comorbidity of cancer and currently has no treatment options. Results from a recent clinical trial at our institution showed that biliary tract cancer patients treated with a MEK inhibitor exhibited poor tumor responses but surprisingly gained weight and increased their skeletal muscle mass. This implied that MEK inhibition might be anticachectic. To test this potential effect of MEK inhibition, we utilized the establish...
11 CitationsSource
#1Casey Ager (University of Texas MD Anderson Cancer Center)H-Index: 5
#2Matthew J. Reilley (University of Texas MD Anderson Cancer Center)H-Index: 5
Last. Sumanta K. Pal (City of Hope National Medical Center)H-Index: 43
view all 1541 authors...
About this supplement These abstracts have been published as part of Journal for ImmunoTherapy of Cancer Volume 4 Suppl 1, 2016. The full contents of the supplement are available online at http://jitc.biomedcentral.com/articles/supplements/volume-4-supplement-1. Please note that this is part 1 of 2.
11 CitationsSource
#1Matthew R. Farren (OSU: Ohio State University)H-Index: 5
#2Reena Shakya (OSU: Ohio State University)H-Index: 15
Last. Gregory B. Lesinski (OSU: Ohio State University)H-Index: 29
view all 13 authors...
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA Selinexor is a SINE (Selective Inhibitor of Nuclear Export) compound that has been administered to >1000 cancer patients in Phase I and II trials to date, with evidence of efficacy and tolerability. This small molecule targets exportin-1 (XPO1), a key nuclear export protein with >200 cargo proteins which include both tumor suppressors and cell cycle modulators. As a result, selinexor blocks nuclear export of proteins...
Source
#1Anne M. Noonan (OSU: Ohio State University)H-Index: 11
#2Matthew R. Farren (OSU: Ohio State University)H-Index: 5
Last. Tanios Bekaii-Saab (OSU: Ohio State University)H-Index: 37
view all 20 authors...
Pelareorep causes oncolysis in tumor cells with activated Ras. We hypothesized that pelareorep would have efficacy and immunomodulatory activity in metastatic pancreatic adenocarcinoma (MPA) when combined with carboplatin and paclitaxel. A randomized phase 2 study (NCT01280058) was conducted in treatment-naive patients with MPA randomized to two treatment arms: paclitaxel/carboplatin + pelareorep (Arm A, n = 36 evaluable patients) versus paclitaxel/carboplatin (Arm B, n = 37 evaluable patients)....
35 CitationsSource
#1Matthew R. Farren (OSU: Ohio State University)H-Index: 5
#2Thomas A. Mace (OSU: Ohio State University)H-Index: 14
Last. Gregory B. Lesinski (OSU: Ohio State University)H-Index: 29
view all 12 authors...
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a 5-year survival rate Experimental Design: Peripheral blood was collected from 73 patients presenting with previously untreated metastatic PDAC. Extensive immunologic profiling was conducted to assess relationships between OS and the level of soluble plasma biomarkers or detailed immune cell phenotypes as measured by flow cytometry. Results: Higher baseline levels of the immunosuppressive cytokines IL6 and IL10 were s...
29 CitationsSource
#1Christopher McQuinn (OSU: Ohio State University)H-Index: 3
#2Thomas A. Mace (OSU: Ohio State University)H-Index: 14
Last. Gregory B. Lesinski (OSU: Ohio State University)H-Index: 29
view all 11 authors...
One hallmark of pancreatic ductal adenocarcinoma (PDAC) is the dense stroma that includes activated myofibroblast-like cells termed ‘pancreatic stellate cells’ (PSC). We hypothesized that antitumor immunity is restrained by PSC, and that key pathways can be identified to augment efficacy of immunotherapy. To gain insight into the most relevant soluble factors and pathways, primary PSC (n=10) were isolated from PDAC patients. A normal human pancreatic fibroblast (HPF) cell line was used as a cont...
#1Daniel H. AhnH-Index: 8
#2Chul AhnH-Index: 63
Last. Tanios Bekaii-SaabH-Index: 37
view all 8 authors...
349 Background: MPDAC is associated with a poor prognosis. The mechanisms of carcinogenesis are complex; involve multiple signaling pathways and inflammatory cytokines that may promote cachexia, a major cause of morbidity and mortality in mPDAC. The purpose of this study is to understand factors related to skeletal muscle changes, and its effect on outcomes in pts with mPDAC. Methods: Pt and clinical data were obtained from a recent prospective clinical trial in mPDAC where all pts received firs...
Source
#1Matthew R. Farren (OSU: Ohio State University)H-Index: 5
#2Thomas A. Mace (OSU: Ohio State University)H-Index: 14
Last. Gregory B. Lesinski (OSU: Ohio State University)H-Index: 29
view all 12 authors...
Background Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that has a 5-year survival rate of less than 7% and is ultimately refractory to most treatments. An assessment of immunologic factors relevant to disease has not been performed in a comprehensive manner for treatment naive patients to date. We hypothesized that systemic immunologic activation and/or immunosuppression would predict overall survival (OS) in treatment naive PDAC patients.
Source
#1Matthew R. Farren (OSU: Ohio State University)H-Index: 5
#2Reena Shakya (OSU: Ohio State University)H-Index: 15
Last. Gregory B. Lesinski (OSU: Ohio State University)H-Index: 29
view all 13 authors...
Exportin-1 (XPO1) is a nuclear export protein with >220 cargo proteins, including tumor suppressors and cell cycle modulators. Selinexor is a SINE (Selective Inhibitor of Nuclear Export) compound that has been administered to >900 cancer patients in Phase I and II trials to date, with evidence of efficacy and tolerability. Selinexor blocks nuclear export of NFAT1c, STAT1 and STAT3, which are implicated in regulating the inhibitory T cell receptor PD-1 and its ligand, PD-L1. We hypothesized that ...
1 CitationsSource
12